CHARLIE CRUCE: Open Payments
NPI 1962044800 · DERMOTT, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$418 in 30 payments from 11 companies in 2025. Trend: 2023 $637 · 2024 $574 · 2025 $418
Food & beverage: $418
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $155 |
| Lundbeck LLC | 4 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| AstraZeneca Pharmaceuticals LP | 2 | $27 |
| PFIZER INC. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Novo Nordisk Inc | 1 | $15 |
Products named: VRAYLAR, REXULTI, CAPLYTA, TRELEGY ELLIPTA, UBRELVY, ELIQUIS, HETLIOZ, JARDIANCE.
Industry payments across AR — which companies pay providers there.
